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Introduction
A cancer cell having stemness can generate tumor tissue, 
which facilitates the recurrence and formation of metastatic 
focus. Therefore, understanding how cancer cells enhance 
their stemness may contribute to cancer therapies.
To evaluate cancer stemness, a sphere formation assay 
with an ultralow attachment dish is widely used. In a 
floating condition with an ultralow attachment dish, a 
solid cancer cell cannot survive for a long time; this 
phenomenon is called anoikis. On the other hand, a 
cancer cell having stemness has anoikis resistance and 
tumor formation ability, which results in survival, pro-
liferation, and formation of a sphere in a floating 
condition.
Among breast cancer subtypes, basal- like breast cancer 
has high stemness [1]. A membrane- bound hyaluronan 
receptor CD44 is known as a factor for stemness [2]. 
In humans, the CD44 gene has various isoforms that 
are generated by alternative splicing of 9 variant exons 
[3]. The CD44 standard form has an extracellular ligand- 
binding region, a transmembrane region, and an intra-
cellular region; however, this form does not contain 
variant exons. CD44 variant isoforms have insertions of 
variant exons between the extracellular and the trans-
membrane regions. The expressions of CD44 variant 
isoforms are used for cancer stem cell markers, as well 
as upregulation of CD44 expression [2, 4, 5]. However, 
not all CD44 isoforms involved in stemness have been 
identified.
Previous studies have identified some splicing factors 
for CD44 isoform expression, such as ESRP1, hnRNPM, 
Tra2- β1, and KHDRBS3 [5–9]. ESRP1 regulates the expres-
sion of variant exons [5, 6]. In contrast, hnRNPM inhibits 
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Abstract
Understanding the mechanism by which cancer cells enhance stemness facilitates 
cancer therapies. Here, we revealed that a stem cell transcription factor, SALL4, 
functions to enhance stemness in basal- like breast cancer cells. We used shRNA- 
mediated knockdown and gene overexpression systems to analyze gene functions. 
To evaluate stemness, we performed a sphere formation assay. In SALL4 knock-
down cells, the sphere formation ability was reduced, indicating that SALL4 
enhances stemness. CD44 is a membrane protein and is known as a stemness 
factor in cancer. CD44 splicing variants are involved in cancer stemness. We 
discovered that SALL4 modulates CD44 alternative splicing through the up-
regulation of KHDRBS3, a splicing factor for CD44. We cloned the KHDRBS3- 
regulated CD44 splicing isoform (CD44v), which lacks exons 8 and 9. CD44v 
overexpression prevented a reduction in the sphere formation ability by KHDRBS3 
knockdown, indicating that CD44v is positively involved in cancer stemness. In 
addition, CD44v enhanced anoikis resistance under the control of the SALL4 
- KHDRBS3 network. Basal- like breast cancer is an aggressive subtype among 
breast cancers, and there is no effective therapy so far. Our findings provide 
molecular targets for basal- like breast cancer therapy. In the future, this study 
may contribute to the establishment of drugs targeting cancer stemness.
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the inclusion of the variant exons in CD44 mRNA [7]. 
Tra2- β1 increases the expression of exons 8 and 9 [8]. 
KHDRBS3 (KH RNA Binding Domain Containing, Signal 
Transduction Associated 3) has been identified as a regu-
lator for CD44 exon 9 [9]. However, the regulation of 
CD44 alternative splicing has not been fully understood 
in basal- like breast cancer.
Developmental transcription factor SALL4 has been 
identified as a factor for cancer cell proliferation in vari-
ous types of cancers mainly though the upregulation of 
a transcriptional repressor of INK4 genes, BMI- 1 [10, 
11]. Recent papers showed a correlation between SALL4 
expression and poor survival rate in patients having 
breast cancer and other kinds of cancers [12, 13]. In 
breast cancer, SALL4 expression was observed in the 
tissues from breast cancer patients [14], and its mRNA 
level was higher in basal- like subtype than in other sub-
types in the cancer genome atlas database [15, 16]. SALL4 
is also expressed in basal- like breast cancer cell lines. 
Therefore, to analyze SALL4 function, shRNA- mediated 
knockdown experiments were conducted in previous 
studies [11, 16]. In basal- like breast cancer, in addition 
to cell proliferation, SALL4 promotes cell migration for 
metastasis by upregulating the expression of integrin 
genes [16]. In addition, previous studies have reported 
that SALL4 is positively involved in tumor formation 
in liver cancer [17, 18]. These suggest that SALL4 pro-
motes cancer malignancy. However, how SALL4 augments 
stemness remains elusive.
Here, we found that SALL4 upregulates a splicing fac-
tor, KHDRBS3. KHDRBS3 changes CD44 isoform expres-
sion. We identified a novel CD44 isoform, which is regulated 
by KHDRBS3 and enhances stemness. Moreover, the SALL4 
- KHDRBS3 - CD44 isoform network augments anoikis 
resistance. Our findings provide a novel mechanism to 
enhance stemness in breast cancer. This study may con-
tribute to the development of cancer therapies targeting 
stemness.
Materials and Methods
Cell culture
Basal- like breast cancer cell lines, SUM159 and Hs578T, 
were obtained from Asterand (Detroit, MI, USA) and the 
American Type Culture Collection (Manassas, VA, USA), 
respectively. SUM159 cells were maintained with Ham’s 
F- 12 nutrient mixture containing 5% FBS, 5 μg/mL insulin, 
1 μg/mL hydrocortisone, and 10 mmol/L HEPES. Hs578T 
cells were cultured with DMEM containing 10% FBS. For 
the cell growth assay, cells were plated with the density 
of 50,000 cells/well, and the cell number was manually 
counted after culturing.
Gene knockdown and overexpression systems
Gene knockdown was performed using the pLKO vector 
(Addgene, 8453, Cambridge, MA, USA). The double- strand 
DNA oligo with shRNA sequence was inserted. The target 
sequences of shRNAs are listed in Supporting table S1. 
Knockdown cells were used 6 days after infection. For 
gene overexpression, pLenti 6.3 vector (Life Technologies, 
V533- 06, Carlsbad, CA, USA) was used. The overexpres-
sion gene was cloned into the pENTR- FLAG vector [19], 
and subcloned into the pLenti 6.3 vector.
Sphere formation assay
For the sphere formation assay, 1000 cells were cultured 
in a well of an ultralow attachment 24- well plate (Corning, 
3473, Kennebunk, ME, USA) with 500 μL of DMEM/F- 12 
medium containing 10 ng/mL EGF, 10 ng/mL basic FGF, 
1% B- 27, 5 μg/mL insulin and 0.03% LA717 (Wako, 381- 
09041, Osaka, Japan). After 16 days, a whole image of 
each well was taken and the number of spheres larger than 
50 μm was manually counted using ImageJ software.
RNA sampling and reverse transcription PCR
Total RNA sample was extracted with TRIzol reagent 
(Thermo Fisher Scientific, 15596026, Waltham, MA, USA). 
A complementary DNA sample was synthesized with 
SuperScript III reverse transcriptase (Thermo Fisher 
Scientific, 18080044) and dT18 primer. Real- time PCR 
was performed with the primers listed in Supporting table 
S2. Relative mRNA level was calculated by ddCt method. 
The sequences of primers for the CD44 variant analysis 
are shown in Supporting table S3.
Immunoblotting
The primary antibodies for immunoblotting are anti- FLAG 
antibody (Wako, 018- 22386, 1/1000 dilution), anti- CD44 
antibody (Thermo Fisher Scientific, MS- 668- P0, 1/1000 
dilution), and anti- β- actin antibody (Abcam, ab6276, 
Cambridge, UK, 1/5000 dilution). Rather than using a 
secondary antibody to detect FLAG and CD44 signals, 
the Easy- Western- II detection system (Beacle, BCL- EZS21, 
Kyoto, Japan) was employed. The secondary antibody to 
detect β- actin signal was goat anti- mouse IgG antibody 
conjugated to a peroxidase (Pierce biotechnology, 31340, 
Rockford, IL, USA, 1/50000 dilution).
Anoikis resistance assay
Anoikis resistance was analyzed using a kit, CytoSelect 
96- well Anoikis Assay (Cell Biolabs, Inc., CBA- 081, San 
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Diego, CA, USA). We used 50,000 cells per well, and 
cultured the cells for 24 h. Calcein AM and EthD- 1 stain-
ing was performed according to the manufacturer’s instruc-
tions. Quantification of anoikis resistance with MTT assay 
was performed according to the manufacturer’s 
instructions.
Statistical analysis
We used Student’s t- test for statistical analyses. P < 0.05 
was considered statistically significant. Error bars show 
standard deviations.
Results
SALL4 enhances stemness in basal- like 
breast cancer cells
To determine whether SALL4 is involved in stemness, we 
used the shRNA- mediated knockdown system [16] and 
performed a sphere formation assay. In a sphere forma-
tion assay, if cells aggregate each other, large clusters are 
observed even if cells do not have sphere formation ability. 
That causes inaccurate results. To avoid cell aggregation 
during culturing, we added the LA717 resin, which blocks 
aggregation through prevention of cell movement in a 
floating condition. When we seeded cells uniformly, each 
sphere was generated from a single cell without aggrega-
tion. In this condition, cell clusters did not grow to a 
large size, and we determined cell clusters larger than 
50 μm in diameter as spheres not generated by aggrega-
tion. We used a basal- like breast cancer cell lines SUM159 
and Hs578T, and observed reduced sphere formation ability 
in SALL4 knockdown cells (Fig. 1A). To quantify the 
difference in sphere formation ability, we counted the 
number of spheres larger than 50 μm. In the results, the 
sphere formation ability of SALL4 knockdown cells was 
significantly reduced, compared to that of the shGFP 
control (Fig. 1B), indicating that SALL4 enhances stemness.
In breast cancer, a change in CD44 alternative splicing 
is involved in stemness [5]. The human CD44 gene has 
9 variant exons that are from exon 6 to 14 (also known 
as variant exon 2 to 10) [20]. We therefore quantified 
the expression levels of the CD44 variant exons and total 
CD44 (Fig. 1C). We observed a reduction in the mRNA 
levels of some variant exons in SALL4 knockdown cells, 
whereas the total CD44 mRNA level was not significantly 
altered by SALL4 knockdown. These results suggest that 
SALL4 modulates CD44 splicing for stemness.
SALL4 regulates KHDRBS3 gene for stemness
Given that SALL4 is a transcription factor, we hypothesized 
that SALL4 regulates the expression of a splicing factor 
Figure 1. SALL4 enhances stemness and modulates the expression of CD44 variant exons. (A) Spheres of the control and SALL4 knockdown cells are 
shown. SUM159 and Hs578T cells were used. Arrowheads indicate spheres larger than 50 μm. (B) Numbers of spheres are graphed. (C) Quantification 
of the expression of CD44 variant exons and total CD44 is shown. Gene structure of CD44 is depicted. The graph shows relative mRNA levels to the 
shGFP control. Scale bar: 100 μm. *P < 0.05, **P < 0.01.
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for CD44 mRNA. In the previously published list of 
SALL4- regulated genes [16], we found the KHDRBS3 gene, 
the product of which is known as a splicing factor for 
CD44 [9]. We analyzed the mRNA level of the KHDRBS3 
gene in SALL4 knockdown cells and observed a reduction 
in KHDRBS3 expression compared to that of the shGFP 
control (Fig. 2A), indicating that SALL4 upregulates 
KHDRBS3 expression. We performed a co- occurrence 
analysis between SALL4 and KHDRBS3 genes in the RNA- 
seq data from breast cancer patients published by the 
cancer genome atlas [21] in the cBioportal platform [22]. 
The result showed that SALL4 and KHDRBS3 expressions 
co- occurred significantly (P = 0.011, Fisher’s exact test), 
which supports our findings.
To determine whether KHDRBS3 is involved in 
stemness, we constructed a KHDRBS3 knockdown sys-
tem (Fig. 2B) and performed sphere formation assays. 
In the results, the sphere numbers of KHDRBS3 knock-
down cells were significantly smaller than that of the 
controls (Fig. 2C). We suspected that if KHDRBS3 
knockdown inhibits cell proliferation, KHDRBS3 knock-
down cells would show a smaller number of spheres 
than the control cells even if the stemness is not 
changed. Therefore, we analyzed cell growth and 
observed no significant difference between the shGFP 
control and KHDRBS3 knockdown cells. These results 
indicate that KHDRBS3 enhances stemness in basal- like 
breast cancer cells.
Figure 2. KHDRBS3 enhances stemness under the control of SALL4. (A) Relative mRNA levels of KHDRBS3 to the shGFP control are shown. SUM159 
and Hs578T cells were used. (B) The efficiency of shRNA- mediated KHDRBS3 knockdown systems is shown. (C) Spheres of the control and KHDRBS3 
knockdown cells are shown. Arrowheads indicate spheres larger than 50 μm. (D) Numbers of spheres are graphed. (E) Cell numbers of the control 
and KHDRBS3 knockdown cells are shown. Scale bar: 100 μm. *P < 0.05, **P < 0.01.
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The SALL4 - KHDRBS3 network enhances 
stemness
To analyze the function of the SALL4 - KHDRBS3 net-
work on stemness, we established KHDRBS3 overexpression 
cells in SUM159 cells (Fig. 3A). We used luciferase2 (Luc2) 
overexpression as the control. SALL4 knockdown reduced 
cell growth as previously reported [11, 18], and KHDRBS3 
overexpression was not able to restore it (Fig. 3B), indi-
cating that KHDRBS3 is not involved in cell growth. We 
performed a sphere formation assay with KHDRBS3- 
overexpressing cells. KHDRBS3 overexpression did not 
increase the sphere formation ability of shGFP cells 
(Fig. 3C,D). Reduced sphere formation ability was observed 
in SALL4 knockdown cells, and KHDRBS3 overexpression 
restored it (Fig. 3C,D), indicating that the SALL4 - 
KHDRBS3 network enhances stemness.
The SALL4 - KHDRBS3 network alters CD44 
splicing for stemness
CD44 has several splicing isoforms with various combina-
tions of variant exons [2]. To identify the isoform regulated 
by KHDRBS3 in basal- like breast cancer, we performed 
reverse transcription PCR with forward and reverse prim-
ers for CD44 designed at exon 5 and 15, respectively. 
The expression pattern of CD44 isoforms was changed 
by KHDRBS3 knockdown (Fig. 4A). Among these isoforms, 
we focused on an isoform of which the expression level 
was reduced to undetectable levels by KHDRBS3 knock-
down (Fig. 4A, arrow). This isoform does not contain 
exon 8 and 9 (hereinafter, referred to the isoform as 
CD44v) (Fig. 4A).
To determine whether CD44v acts as a stemness factor 
under the control of the SALL4 - KHDRBS3 network, 
we introduced CD44v overexpression into SUM159 cells 
(Fig. 4B) and performed a sphere formation assay in 
combination with KHDRBS3 knockdown experiments. In 
the Luc2 control cells, KHDRBS3 knockdown reduced 
sphere formation ability (Fig. 4C,D). This reduction was 
not observed in CD44v- overexpressing cells (Fig. 4C,D). 
These results suggest that the SALL4 - KHDRBS3 network 
enhances stemness through the regulation of CD44 
splicing.
The SALL4 - KHDRBS3 - CD44v network 
enhances anoikis resistance
Anoikis resistance is one of the hallmarks of stemness in 
cancer and is required for sphere formation. To determine 
whether the SALL4 - KHDRBS3 - CD44v network enhances 
anoikis resistance, we performed an anoikis assay in the 
control cells and CD44v- overexpression cells with or with-
out KHDRBS3 knockdown. In the results, EthD- 1- stained 
dead cell signals were increased by KHDRBS3 knockdown 
in Luc2 control cells (Fig. 5A). However, such signals 
were not increased by KHDRBS3 knockdown in CD44v- 
overexpressing cells (Fig. 5A). To evaluate anoikis resist-
ance, we quantified living cell values with an MTT assay. 
Reduced anoikis resistance by KHDRBS3 knockdown was 
not observed in CD44v- overexpressing cells (Fig. 5B), 
suggesting that the SALL4 - KHDRBS3 - CD44v network 
Figure 3. The SALL4 - KHDRBS3 network enhances stemness. (A) KHDRBS3- overexpressing cells were established. Immunoblotting images are 
shown. (B) The results of cell growth assay are shown. Student’s t- test was performed against the values of Luc2; shGFP cells. (C) Spheres of the 
control and SALL4 knockdown cells are shown. Arrowheads indicate spheres larger than 50 μm. (D) Numbers of spheres are graphed. Scale bar: 
100 μm. **P < 0.01.
459© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
SALL4 - KHDRBS3 - CD44v Network Promotes StemnessY. Matsumoto et al.
provides stemness through enhancement of anoikis 
resistance.
In our experiments (Fig. 5), CD44v overexpression did 
not increase anoikis resistance in the shGFP control cells. 
This suggests that although CD44v is required for anoikis 
resistance, it is not a factor to enhance anoikis resistance. 
Another suggestion is that this cell line already has the 
maximum level of anoikis resistance, and CD44v overex-
pression could not increase it.
Discussion
Cancer stemness is one of the factors for recurrence and 
formation of a metastatic focus. In this study, we showed 
that SALL4 enhances stemness and modulates the expression 
of CD44 variant exons through upregulation of KHDRBS3 
expression. We identified the CD44 isoform under the con-
trol of the SALL4 - KHDRBS3 network. Overexpression of 
the isoform (called CD44v in this study) restored the reduced 
sphere formation ability by KHDRBS3 knockdown, indicat-
ing that the SALL4 - KHDRBS3 network- regulated CD44v 
enhances stemness. In addition, we discovered that CD44v 
expression augments anoikis resistance.
In gastric cancer, SALL4 upregulates CD44 expression 
[23]. However, we observed no significant change in the 
total CD44 expression level by SALL4 knockdown, indicating 
that SALL4 does not regulate CD44 transcription in basal- 
like breast cancer cells. This difference suggests that the 
regulatory mechanism of CD44 expression differs between 
gastric cancer cells and basal- like breast cancer cells.
CD44 has splicing isoforms [2]. CD44 variants contain 
variant exon(s) in their mRNA, while CD44 standard does 
not have variant exons. Among CD44 variants, the isoform 
having exon 10 is known as a stemness factor in cancer 
[24]. In a non- metastatic rat pancreatic carcinoma cell 
line, overexpression of an exon 10- containing isoform of 
CD44 provided a metastatic potential [25]. Anti- CD44 
exon 10 antibody blocked metastasis [26]. Patients having 
colorectal cancer with high expression of CD44 exon 6 
had a poor prognosis [27]. This study identified a novel 
splicing isoform, CD44v, which does not have exon 8 
and 9. Although this isoform had not been identified as 
a stemness factor, it contains exons 6 and 10, which is 
consistent with previous studies [24, 27].
In cancer, it has been reported that Serpin B5 interacts 
with KHDRBS3 and FBXO32 in gastric cancer and acts as 
an oncogenic factor [28]. However, the function of KHDRBS3 
on cancer stemness remained unknown. We showed that 
KHDRBS3 enhances stemness in basal- like breast cancer. 
This study identified KHDRBS3 as a regulator for CD44v 
under the regulation of SALL4. This finding differs from 
the previous study, which reported that KHDRBS3 functions 
Figure 4. KHDRBS3- modulated CD44 isoform enhances stemness. (A) An agarose gel electrophoresis image of CD44 variant expression is shown. 
Arrow indicates the isoform on which we focused in this study (CD44v). The structure of CD44v is depicted. (B) CD44v- overexpressing cells were 
established. Immunoblotting images are shown. (C) Spheres of the control and KHDRBS3 knockdown cells are shown. ShKHDRBS3 #1 was used. 
Arrowheads indicate spheres larger than 50 μm. (D) Numbers of spheres are graphed. Scale bar: 100 μm. *P < 0.05, **P < 0.01.
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to express exon 9 [9]. This seems to be due to the differ-
ence in cell lines and/or conditions. Alternative splicing is 
regulated by a combination of splicing factors [7, 29]. Given 
that CD44 has 9 variant exons and the regulation of the 
expression of these exons is complex, SALL4- regulated 
KHDRBS3 expression seems to be one of the factors for 
CD44 variant expression in basal- like breast cancer.
CD44 is used as a marker for stemness in breast cancer 
[2, 30]. The expression of CD44 variant exons increases 
metastasis [25]. However, the mechanism how CD44 con-
tributes to stemness and metastasis has not been fully 
studied. Anoikis resistance is involved in both stemness 
and metastasis. This study focused on stemness in basal- 
like breast cancer, and discovered that CD44v increases 
anoikis resistance. Although various factors contribute to 
cancer stemness and metastasis, and further study is required 
to understand the function of CD44, we revealed one of 
the regulatory mechanisms of anoikis resistance.
SALL4 is a transcription factor, and SALL4 knockdown 
changes various cellular events. Although some SALL4- 
regulated genes involving in breast cancer malignancy have 
been identified, how SALL4 promotes stemness remained 
elusive. This study revealed that SALL4 regulates CD44v 
expression via KHDRBS3 for stemness, which might contribute 
to understanding of the function of SALL4 on cancer stemness.
In our observation, change in the pattern of the variant 
exon expression differed between SALL4 and KHDRBS3 
knockdowns. These suggest that SALL4 knockdown influ-
ences the expression and/or function of other splicing 
factors. As for the stemness of basal- like breast cancer, 
our KHDRBS3 overexpression experiments showed preven-
tion of the reduction in sphere formation ability by SALL4 
knockdown. This indicates that although other splicing 
factors might function to regulate CD44 alternative splicing 
under the control of SALL4, the SALL4 - KHDRBS3 net-
work contributes to stemness in basal- like breast cancer.
Currently the major therapeutic approach for basal- like 
breast cancer is chemotherapy, and there is no targeted 
therapy approved for this subtype of breast cancer. We 
discovered a novel molecular network for stemness, which 
could be a therapeutic target. Our findings may contribute 
to the development of stemness- targeted therapy.
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